Remove 2009 Remove Competition Remove Prospecting
article thumbnail

Optimising bispecific antibody clonal cell selection with high-throughput analytics

European Pharmaceutical Review

The success of the MCB choice impacts both regulatory approval prospects and the manufacturability of the bsAb. competitive binding-MS for analysis of multiple PQAs and rapid HT N-glycan analysis using combined LC/MS. 2017 Aug 1;28(8):2009-2012. capillary electrophoresis (CE) for HT glycan screening of clones. 2021.102240.

article thumbnail

The Fastest Growing Companies in Boston Hiring For Sales

CloserIQ

Drift provides a conversational sales and marketing platform that allows businesses to better connect with prospects and customers. Founded 2009. Cybereason’s workplace culture is known to be fast-paced and competitive, with plenty of opportunities for learning. Salsify offers competitive benefits and a flexible vacation plan.

Sales 76
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Redesigning Provider Incentives to Influence Practice Patterns and Performance

Clarify Health

Baptist Health System (BHS), a clinically integrated network of five hospitals in San Antonio, Texas, entered the Medicare Acute Care Episodes (ACE) program in 2009 and implemented behavioral economics to incentivize clinician performance. million on orthopedic MS-DRGs.[1]

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.

article thumbnail

FDA sketches a path for patient-focused drug development

Pharmaceutical Technology

The draft guidance, released on March 5, is open for comments until May 7, after which it will replace an earlier 2009 guidance for the industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.